Achieve Life Sciences (ACHV) Prices 476.19K Share Common Offering at $10.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
After-Hours Movers 08/03: (YRCW) (SEDG) (VRNS) Higher; (IMUX) (AIHS) (SPCE) Lower (more...)
August 3, 2020 6:14 PM EDTAfter-Hours Stock Movers:
YRC Worldwide (NASDAQ: YRCW) 45% HIGHER; reported Q2 EPS of ($1.09), $0.29 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.01 billion.
SolarEdge Technologies (NASDAQ: SEDG) 12% HIGHER; reported Q2 EPS of $0.70, $0.01 better than the analyst estimate of $0.69. Revenue for the quarter came in at $331.9 million versus the consensus estimate of $319.42 million. SolarEdge Technologies sees Q3 2020 revenue of $325-350 million, versus the consensus of $330.8... More
Achieve Life Sciences (ACHV) Announces Proposed Common Share Offering
August 3, 2020 4:01 PM EDTAchieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its... More
Achieve Life Sciences (ACHV) Announces Patent Granted in U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
July 31, 2020 8:32 AM EDTAchieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of... More
